Diabetic Angiopathies (Diabetic Angiopathy)

Subscribe to Selected New Research on Diabetic Angiopathies

918 relevant articles (28 outcomes, 103 trials/studies) found for this Disease

Description: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Also Known As:

Diabetic Angiopathy; Angiopathy, Diabetic; Angiopathies, Diabetic; Diabetic Microangiopathies; Diabetic Microangiopathy; Diabetic Vascular Complication; Diabetic Vascular Disease; Microangiopathies, Diabetic; Vascular Complication, Diabetic; Vascular Complications, Diabetic; Vascular Disease, Diabetic; Vascular Diseases, Diabetic; Diabetic Vascular Complications; Diabetic Vascular Diseases; Microangiopathy, Diabetic

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18449

Vascular Diseases: 7172

Diabetic Angiopathies: 918

Diabetic Retinopathy: 4760

Diabetic Foot: 818

Endocrine System Diseases: 390

Diabetes Mellitus: 22586

Diabetes Complications: 2235

Diabetic Angiopathies: 918

Diabetic Retinopathy: 4760

Diabetic Foot: 818

Related Diseases

1.	Albuminuria
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes)
3.	Hyperglycemia
4.	Atherosclerosis (Atheroma)
5.	Edema
102 Diseases and 229 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Cesarone, M R: 7 articles (08/2006 - 12/2001)
2.	Belcaro, G: 7 articles (08/2006 - 12/2001)
3.	Ricci, A: 5 articles (08/2006 - 12/2001)
4.	Yamagishi, Sho-ichi: 4 articles (01/2008 - 02/2005)
5.	Dugall, M: 4 articles (08/2006 - 01/2002)
6.	Acerbi, G: 4 articles (08/2006 - 01/2002)
7.	Griffin, M: 4 articles (07/2003 - 12/2001)
8.	Incandela, L: 4 articles (01/2002 - 12/2001)
9.	Nakamura, Kazuo: 3 articles (01/2008 - 02/2005)
10.	Imaizumi, Tsutomu: 3 articles (01/2008 - 02/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Diabetic Angiopathies:

1.	Insulin (Novolin)FDA Link 12/01/1993 - "In insulin-dependent and non insulin-dependent diabetic patients, the treatment of a modest increase in blood pressure values has been proved effective in reducing the incidence and in improving the evolution of various locations of diabetic angiopathy" 12/01/2002 - "In conclusion insulin appears to regulate shedding or clearance of VAP-1, and an increase in sVAP-1 because of absolute or relative insulin deficiency may be directly involved in the pathogenesis of diabetic angiopathy." 11/01/2004 - "The study confirms the crucial role of intensive insulin therapy and systematic patients' education concerning the disease in maintaining a good metabolic control and thus reducing the risk of diabetic vascular complications." 10/01/1991 - "Factors associated with diabetic microangiopathy: a study of 157 type I (insulin-dependent) diabetic patients." 03/01/2007 - "CONCLUSIONS/INTERPRETATION: These data suggest that patients with fulminant type 1 diabetes are a high-risk subgroup for diabetic microangiopathy associated with the lack of endogenous insulin secretion from the onset of diabetes." Get all the results and reference details, order at left...
2.	Blood Glucose (Blood Sugar)IBA 04/15/1988 - "Tight control of blood sugar in close association with antihypertensive treatment reducing blood pressure to a lower normal limit, possibly with agents that specifically decrease glomerular capillary hydraulic pressure are the corner stone in protection against progression of the diabetic angiopathy." 07/01/1999 - "Blood glucose control as well as blood pressure control are important in the prevention of diabetic vascular complications as evidenced by large-scale interventional studies." 05/01/1995 - "From this study, the glycemic threshold to prevent the onset and the progression of diabetic microangiopathy is indicated as follows; HbA1c < 6.5%, FBG < 110 mg/dl, and 2-h post-prandial blood glucose concentration < 180 mg/dl." 01/16/1982 - "This interim report of a one-year study supports the view that long-term control achieving near-normal blood-glucose levels may arrest or even reverse some of the features associated with diabetic microangiopathy." 12/01/2006 - "Our data suggest that serum HA level correlates with poor blood glucose control and diabetic angiopathy and that it could be used as a marker of diabetic angiopathy." Get all the results and reference details, order at left...
3.	Carbon MonoxideIBA 10/01/1981 - "The improved technique reported here should facilitate study of the platelet hyperaggregation co-factor and the pathophysiology of diabetic microangiopathy." 01/01/2001 - "RESULTS: We found a significant reduction in lung diffusion capacity for carbon monoxide (DL(CO)) in the group of patients with other signs of diabetic microangiopathy (p < 0.005) and a significative correlation between DL(CO )and the grade of albuminuria (r = -0.83, p < 0.001)" 05/01/1988 - "Impaired carbon monoxide gas transfer has been demonstrated in patients with insulin-dependent diabetes mellitus (IDDM), but no relationship has been documented between impairment of gas transfer and the presence of other clinical evidence of diabetic microangiopathy" 01/01/1999 - "In 20 patients with diabetic angiopathy of lower extremities and purulent-necrotic complications, in whom the diagnosis of chronic syndrome of disseminated intravascular blood coagulation (DIC-syndrome), preparation vobenzym (Mucos Pharma & Co, Germany) was applied" Get all the results and reference details, order at left...
4.	Gliclazide (Diamicron)IBA 01/07/1988 - "Previous studies have suggested that the sulphonylurea hypoglycaemic agent gliclazide has specific effects in inhibiting platelet aggregation, and other haemorrheological effects that could be beneficial in preventing diabetic microangiopathy" 03/01/1987 - "Thus, this study did not detect a reversal of the parameters measured and does not support an action of gliclazide on diabetic microangiopathy, independent of its hypoglycaemic action." 03/01/1987 - "This study has attempted to document a specific haemovascular action of gliclazide on the reversal of early diabetic microangiopathy" 08/01/2003 - "In addition, gliclazide MR shows the ability to inhibit key mechanisms in diabetic angiopathy, independently of glycemic control." 10/01/2000 - "In diabetes, therefore, where increased glycation and oxidation are fundamental to the pathogenesis of diabetic vascular disease, agents such as gliclazide with its antioxidant activities may have an enhanced therapeutic role." Get all the results and reference details, order at left...
5.	Pentoxifylline (Trental)FDA LinkGeneric 01/01/1985 - "The results of this study suggest that pentoxifylline is an effective drug for the long-term treatment of diabetic vascular complications and that it may also possibly depress or prevent the progress of the disease." 04/01/1981 - "Trials of trental in treatment of diabetic angiopathy (author's transl)]" 01/01/1982 - "Treatment of diabetic angiopathy with pentoxifylline]" 01/01/1978 - "Therapeutic effect of Trental in diabetic angiopathy]" 01/01/1983 - "The purpose of our study was to verify the possibility of obtaining a reduction in the erythrocyte filtration rate and an improvement in the O2 tissue uptake in twenty patients suffering from insulin-dependent diabetes mellitus and diabetic angiopathy, randomly divided in two groups receiving pentoxifylline (1,200 mg/day for 30 days) or a placebo solution, respectively" Get all the results and reference details, order at left...
6.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/01/1986 - "Trial of repeated low-dose aspirin in diabetic angiopathy." 10/01/1982 - "5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid]" 05/15/1979 - "In the present survey the hitherto existing reports from literature are critically summarized, taking into particular consideration the per ipheral angioorganopathies and first informations on an own study concerning the prophylaxis of the diabetic angiopathy with Micristin are given" 01/01/2004 - "Aspirin resistance and diabetic angiopathy: back to the future." 10/01/1986 - "Similar gaps were also found for diabetics, but not for normals, following four daily doses (every six hours) of 25 or 100 mg. Our data show that dose schedules of aspirin which may suffice in normals are not effective in patients with diabetic angiopathy, presumably because these patients have a high rate of entry of new platelets into the circulation" Get all the results and reference details, order at left...
7.	Advanced Glycosylation End ProductsIBA 05/01/2000 - "CONCLUSION/INTERPRETATION: Cross-link breakers seem to be effective in preventing or reversing accumulation of advanced glycation end-products in blood vessels and have the potential to play a part in the treatment of diabetic vascular complications." 03/28/1997 - "This study was undertaken to determine whether and how advanced glycation end products (AGE), senescent macroproteins accumulated in various tissues under hyperglycemic states, cause angiogenesis, the principal vascular derangement in diabetic microangiopathy" 08/01/2008 - "BACKGROUND: The binding of advanced glycation end-products (AGEs) to their receptor for AGEs (RAGE) may play an important role in the development of diabetic vascular complications" 01/01/2008 - "Advanced glycation end products (AGEs)-their receptor (RAGE) axis plays a central role in the pathogenesis of diabetic microangiopathy" 07/01/2007 - "BACKGROUND AND AIM: Advanced glycation end products (AGE), senescent macroprotein derivatives formed at an accelerated rate in diabetes, play important roles in the pathogenesis of diabetic vascular complications" Get all the results and reference details, order at left...
8.	Vitamin E FDA Link 12/01/1993 - "Controlled studies are needed to confirm the effect of vitamin E on platelet function in well-defined groups of diabetics, followed by large-scale trials investigating the prevention of diabetic vascular complications as clinical end point." 11/01/2004 - "Adolescents with early signs of diabetic angiopathy have defective IAP and activity, which are not modified by vitamin E." 01/01/1998 - "4. CONCLUSIONS: Our study suggests that vitamin E supplementation may improve the increased platelet adhesion as a consequence of an increased oxidative stress and therefore the incidence of diabetic angiopathy may be reduced." 05/01/1990 - "These results indicate that vitamin E may improve platelet function and prostaglandin metabolism in diabetes mellitus and may be able to provide further beneficial effects in relation to the development of diabetic vascular complications." 09/01/1988 - "Because increased TXA2 production of diabetic platelets is thought to play an important pathogenetic role in diabetic angiopathy, we conclude that vitamin E treatment could be beneficial with respect to platelet-vessel-wall interaction and thus might be promising for the prevention of diabetic angiopathy." Get all the results and reference details, order at left...
9.	Growth Hormone (Somatotropin)IBA 01/01/1991 - "Disturbed function of the axis hypothalamus-growth hormone-somatomeding C (IGF-1) plays an important role in the development of diabetic angiopathy" 04/01/1989 - "Excess production of growth hormone (GH) in poorly controlled diabetes is believed to be a causal factor in the development of diabetic angiopathy, the mechanism(s) of which is unknown" 02/15/1979 - "Thus, these results suggest that a positive correlation exists between alterations in the secretion of growth hormone and the development of diabetic microangiopathy." 12/01/1978 - "The possible significance of this effect of an elevated level of growth hormone for diabetic microangiopathy is discussed." 01/01/1977 - "The dynamics of growth hormone secretion in various stages of diabetic microangiopathy development." Get all the results and reference details, order at left...
10.	CollagenIBA 07/01/1988 - "The increased collagen binding activity was associated in postpubertal patients with the presence of diabetic microangiopathy, suggesting a pathogenetic role." 11/01/1984 - "Collagen distruction prevailed over its biosynthesis in development and progress of diabetic microangiopathies, that resulted in the increased FH/PBH coefficient" 02/01/1980 - "Collagen metabolism in diabetic microangiopathies]" 12/01/1975 - "These measurements allow quantification of basement membrane collagen and may be used to follow development of diabetic vascular complications." 11/15/1991 - "It is concluded that, in addition to deformity of nailfold capillaries, collagen deposition may also be a sign of metabolic disturbance and perhaps of proliferation of capillary endothelial cells in diabetic microangiopathy." Get all the results and reference details, order at left...
405 Drugs and Important Bio-Agents and 856 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Laser Therapy (Surgery, Laser) 10/01/1996 - "A course of magnetic-laser therapy results in significant reduction of concentration of the lipid oxidation products as one of the pathogenetic mechanisms of diabetic microangiopathies, normalization of immunologic reactivity as well as attenuation of clinical manifestations of hemocirculatory disorders in the lower extremities and improvement of parameters of thermo- and rheovasography." 10/01/1996 - "The medical effect of magnetic-laser therapy in patients with diabetic angiopathies of the lower extremities]" Get all the results and reference details, order at left...
2.	Hemodilution 01/01/1996 - "Prolonged normovolemic hemodilution (PNH) was shown to be highly effective in treatment of 87 patients with diabetic angiopathies of the lower extremity vessels" 01/01/1996 - "Experience in using prolonged normovolemic hemodilution in patients with diabetic angiopathies of the vessels of the lower extremities]" Get all the results and reference details, order at left...
3.	Lasers (Laser) 09/01/2002 - "Our data show a significant increase in skin circulation due to athermic laser irradiation in patients with diabetic microangiopathy and point to the possibility of inducing systemic effects." 09/01/2002 - "We therefore investigated such a potential systemic effect of low-intensity laser irradiation on skin blood circulation in patients with diabetic microangiopathy" 09/01/2002 - "Systemic effects of low-intensity laser irradiation on skin microcirculation in patients with diabetic microangiopathy." 04/01/2001 - "Other investigations such as TcPO(2) measurement, laser-Doppler and capillaroscopy are useful for revealing early functional diabetic microangiopathy, but they can only be done and interpreted in specialized centers." 04/01/1998 - "CONCLUSIONS: The data from this first randomized double-blind placebo-controlled clinical trial demonstrate an increase in skin microcirculation due to athermic laser irradiation in patients with diabetic microangiopathy." Get all the results and reference details, order at left...
4.	Compression Stockings 12/01/1993 - "Microcirculatory effects of elastic stockings in diabetic microangiopathy: a 24-week study." 01/01/1990 - "However further studies, treating with elastic compression more patients for longer periods, are needed to confirm the positive effects of elastic stockings in improving diabetic microangiopathy and in slowing down its rate of progression." 12/01/1993 - "Elastic stockings seem to be useful in diabetic microangiopathy improving microcirculatory parameters and decreasing capillary filtration and oedema" 01/01/1992 - "Seventy four patients were advised to wear elastic stockings and 75 were kept as controls with the aim of evaluating the effects of stockings on the evolution of diabetic microangiopathy" 01/01/1992 - "Elastic stockings in diabetic microangiopathy" Get all the results and reference details, order at left...
5.	Pancreas Transplantation 08/31/1991 - "The effects of pancreas transplantation on diabetic microangiopathy are difficult to evaluate in these patients who often have very advanced complications, but the first data are encouraging" 10/01/1990 - "Does combined kidney and pancreas transplantation reverse functional diabetic microangiopathy?" 02/01/1989 - "Evidence for reversibility of diabetic microangiopathy following pancreas transplantation." 06/01/1988 - "Pancreas transplantation: curative therapeutic approach to diabetic microangiopathy?" 10/01/1987 - "Changes of diabetic microangiopathy after pancreas transplantation." Get all the results and reference details, order at left...
38 Therapies and Procedures and 77 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Diabetic Angiopathies

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 28 Outcomes
Top 200 Key Medications
Top 38 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>